

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6295732

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUN WOO HONG	11/26/2014
RECEIVING PARTY DATA	
Name:	OLIX PHARMACEUTICALS, INC.
Street Address:	#1014 GWANGGYO ACE TOWER 1
Internal Address:	17, DAEHAK 4-RO, YEONGTONG-GU
City:	SUWON-SI, GYEONGGI-DO
State/Country:	KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
Postal Code:	16226
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16135766
CORRESPONDENCE DATA	
Fax Number:	(202)739-3001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-739-3000
Email:	patents@morganlewis.com, amanda.mcintyre@morganlewis.com
Correspondent Name:	MORGAN, LEWIS, & BOCKIUS LLP (B0)
Address Line 1:	1111 PENNSYLVANIA AVENUE, NW​
Address Line 4:	WASHINGTON, D.C. 20004-2541
ATTORNEY DOCKET NUMBER:	OLX-007C1/116825-5007
NAME OF SUBMITTER:	INNA DAHLIN
SIGNATURE:	/Inna Dahlin/
DATE SIGNED:	09/14/2020
Total Attachments: 2	
source=OLX-007_Executed_Assignment#page1.tif	
source=OLX-007_Executed_Assignment#page2.tif	

ASSIGNMENT

I, SUN WOO HONG, have made an invention the specification of which is described in the U.S. Patent Application No. 14/403,121 filed under the provisions of 35 U.S.C. § 371, based on International Patent Application No. PCT/KR13/04463 filed on May 21, 2013, entitled:

"RNA-INTERFERENCE-INDUCING ACID MOLECULE ABLE TO PENETRATE INTO CELLS, AND USE THEREFOR"

I hereby assign to Olix Pharmaceuticals Inc., Rm 1305, Star Valley, 99, Digital-ro 9-gil, Gaseong-gu, Seoul 153-777, Republic of Korea, all ownership and rights in:

- (i) the invention and U.S. Patent Application;
- (ii) non-provisional, continuing, divisional and continuation-in-part applications based on and claiming benefit and/or priority of said U.S. Patent Application; and
- (iii) U.S. Patents on the invention.

I am making this assignment based on my business relationship with Olix Pharmaceuticals Inc.

I respectfully request the Commissioner for Patents of the United States to issue patents on the invention to:

Olix Pharmaceuticals Inc.


as owner of the invention and aforementioned patent rights.

I agree to execute any other legal documents that may be required to effectuate this Assignment.

I agree that I will promptly communicate to Olix Pharmaceuticals Inc. all facts which come to my attention affecting the invention or patent rights.

I agree that I will testify in any interference or litigation involving the invention or patent rights.

I declare that I have not done anything in conflict with this Assignment.



SUN WOO HONG

11/26/2014

Date (mm/dd/yyyy)

STATEMENT OF INVENTOR

A duty of disclosure is imposed by 37 CFR § 1.56 on all inventors of the subject matter claimed in an application, and on anyone else reviewing, contributing to, or approving the application. All material information known to persons under the duty of disclosure must be identified to the United States Patent and Trademark Office. All inventors must be aware of the duty of disclosure.

This information can exist in many forms - patents, published patent applications, books, scientific journals, trade newsletters, mass market periodicals, product literature, promotional flyers, business announcements, Web pages, or other sources of tangible information. It can also exist in intangible form, such as knowledge or awareness of events (examples: a non-confidential demonstration of a product or technology; information derived by visual observation during a tour of a laboratory or industrial production facility; and non-confidential sampling of a material).

All such information should be brought to the attention of Hultquist IP so that we can determine whether it is in fact material, and so that we can then disclose all appropriate information to the United States Patent and Trademark Office. Failure to observe the duty of disclosure is regarded as inequitable conduct and can result in loss of the validity and enforceability of patent rights. The duty of disclosure continues throughout the entire patenting procedure, from the time that a patent application is filed, until a patent is issued on the application or the application is abandoned.

By signing my name below, I am attesting that I have read and understand U.S. Patent Application No. 14/403,121, including the claims in such application, and that I am aware of the duty of disclosure as explained in this document.


Sun Woe Hong

11/26/2017
Date (mm/dd/yyyy)